GlaxoSmithKline Consumer Healthcare has announced the approval of Flonase Allergy Relief fluticasone propionate nasal spray for the treatment of allergic rhinitis for over-the-counter (OTC) sales in Canada. The nasal spray will be available OTC for patients 18 years old and over beginning in early 2017. GSK President of Consumer Healthcare North America Colin … [Read more...] about Flonase Allergy Relief approved for OTC sales in Canada
News
Adherium announces management changes
Smartinhaler developer Adherium Limited has announced that Thomas Lynch has been appointed the company's new Chairman and that Doug Wilson will step down from the board to take on the role of Medical Director on a part time basis. Lynch recently retired from his role as Chair of ICON after serving on that company's board for over 20 years. He currently serves as … [Read more...] about Adherium announces management changes
Gateway Analytical moves to larger facility
Particle characterization specialist Gateway Analytical will move to a new 17,000 sq ft (1,580 sq m) laboratory and office space in Gibsonia, Pennsylvania on September 1, 2016, according to an announcement by its parent company, ChemImage. Gateway Analytical's services for OINDP testing include ingredient-specific particle size analysis, agglomerate analysis, and … [Read more...] about Gateway Analytical moves to larger facility
Flutiform fails to meet primary endpoint in Phase 3 trial for COPD
According to Vectura, Mundipharma's Phase 3 trial of the flutiform fluticasone/formoterol MDI failed to demonstrate statistically significant superiority compared to formoterol alone in reducing moderate and severe COPD exacerbations. Mundipharma had planned to seek approval from European regulators to market flutiform for the treatment of COPD but will now put off … [Read more...] about Flutiform fails to meet primary endpoint in Phase 3 trial for COPD
Qualcomm to collaborate with Boehringer Ingelheim on connected Respimat inhaler
Boehringer Ingelheim and Qualcomm Life have agreed to collaborate on development of a disposable wireless data sensor module for BI's Respimat inhaler for COPD treatment. The sensor will connect with Qualcomm Life's 2net platform. Qualcomm had previously announced that it would develop a disposable sensor module for Novartis's Breezhaler. Boehringer Ingelheim … [Read more...] about Qualcomm to collaborate with Boehringer Ingelheim on connected Respimat inhaler
Japanese regulators approve additional dosage regimen for the Inavir DPI
Daiichi Sankyo has announced that Japanese regulators have approved the use of its Inavir laninamivir octanoate hydrate DPI for the prevention of influenza in single doses of 20 mg for children under 10 years old and single doses of 40 mg for anyone older than 10. Inavir was approved in Japan for the treatment of influenza A and B in 2010 and for the prevention of … [Read more...] about Japanese regulators approve additional dosage regimen for the Inavir DPI
Spyryx Biosciences appoints Alistair Wheeler as Chief Medical Officer
Spyryx Biosciences, which is developing an inhaled peptide for the treatment of cystic fibrosis and other respiratory diseases, has announced the appointment of former Sunovion Head of Clinical Research Alistair Wheeler as Chief Medical Officer, a newly created position. Spyryx's SPX-101 is currently in Phase 1 development for the treatment of cystic fibrosis. … [Read more...] about Spyryx Biosciences appoints Alistair Wheeler as Chief Medical Officer
Paradigm Biopharmaceuticals completes Phase 1 trial of pentosan polysulfate sodium nasal spray
Paradigm Biopharmaceuticals has announced the completion of a Phase 1 clinical trial of its Rhinosul pentosan polysulfate sodium (PPS) nasal spray for allergic rhinitis. Paradigm said that none of the 18 healthy volunteers involved in the study experienced any significant adverse effects and that it anticipates the final report in October 2016. The company also … [Read more...] about Paradigm Biopharmaceuticals completes Phase 1 trial of pentosan polysulfate sodium nasal spray
Pulmatrix’s PUR1900 itraconazole DPI gets orphan drug designation
According to Pulmatrix, the FDA has granted orphan drug status to the company's PUR1900 itraconazole DPI for the treatment of fungal lung infections in cystic fibrosis patients, with the FDA stating, "Your designation is based on a plausible hypothesis that your drug may be clinically superior to the same drug that is already approved for the same indication." The … [Read more...] about Pulmatrix’s PUR1900 itraconazole DPI gets orphan drug designation
Phillips-Medisize to be acquired by Molex
Molex, which describes itself as "a global manufacturer of complete interconnect solutions," will acquire device developer and manufacturer Phillips-Medisize from Golden Gate Capital, the company said. The financial terms of were not disclosed. Phillips-Medisize was acquired by Golden Gate Capital in 2014 and earlier this year announced that it would acquire … [Read more...] about Phillips-Medisize to be acquired by Molex